Literature DB >> 16876514

Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma.

Ingo Schmack1, G Baker Hubbard, Shin J Kang, Thomas M Aaberg, Hans E Grossniklaus.   

Abstract

PURPOSE: To report four cases of optic nerve neuropathy in three children treated with periocular carboplatin injections for unilateral or bilateral intraocular retinoblastoma.
DESIGN: Retrospective, observational case series.
SETTING: University-based Ophthalmology Practice. STUDY POPULATION: Four eyes of three children with retinoblastoma enucleated after nonsuccessful multimodality treatment including periocular carboplatin injections. OBSERVATION PROCEDURES: The enucleated eyes were routinely processed and evaluated by light microscopy. A retrospective chart review of all four cases was performed.
RESULTS: Three enucleated eyes (Reese-Ellsworth groups III and VB) were obtained from two children with bilateral multifocal retinoblastoma, and one eye (Reese-Ellsworth group IIB) was harvested from a child with unilateral retinoblastoma. All affected eyes underwent three to seven periocular carboplatin injections before enucleation. Additional treatment modalities included systemic chemotherapy, transpupillary thermotherapy, transscleral cryotherapy, and external beam radiotherapy. Histopathologic evaluation of the enucleated eyes revealed focal areas of ischemic necrosis or atrophy of the optic nerve along with dystrophic calcification and mild inflammation in the surrounding fibrovascular adipose tissue.
CONCLUSIONS: Periocular injections of carboplatin may be a useful treatment approach in the management of patients with advanced intraocular retinoblastoma and may minimize systemic side-effects. However, ophthalmologists and pediatric oncologists should be aware of potential marked local complications with periocular carboplatin delivery, including ischemic optic neuropathy. Modifying the injection site/location (for example, subtenon space) or adding other delivery routes adjuncts (for example, fibrin sealant) deserves further study.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16876514     DOI: 10.1016/j.ajo.2006.02.044

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  21 in total

1.  Retinoblastoma. Fifty years of progress. The LXXI Edward Jackson Memorial Lecture.

Authors:  Hans E Grossniklaus
Journal:  Am J Ophthalmol       Date:  2014-07-24       Impact factor: 5.258

2.  Severe Periocular Edema after Intraarterial Carboplatin Chemotherapy for Retinoblastoma in a Rabbit (Oryctolagus cuniculus) Model.

Authors:  Tai L Oatess; Patty H Chen; Anthony B Daniels; Lauren E Himmel
Journal:  Comp Med       Date:  2020-03-11       Impact factor: 0.982

Review 3.  Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.

Authors:  Uma M Sachdeva; Joan M O'Brien
Journal:  J Clin Invest       Date:  2012-02-01       Impact factor: 14.808

4.  Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma.

Authors:  Shin J Kang; Chandrasekar Durairaj; Uday B Kompella; Joan M O'Brien; Hans E Grossniklaus
Journal:  Arch Ophthalmol       Date:  2009-08

Review 5.  Current update on retinoblastoma.

Authors:  Samuel K Houston; Timothy G Murray; Stacey Quintero Wolfe; Cristina E Fernandes
Journal:  Int Ophthalmol Clin       Date:  2011

Review 6.  Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.

Authors:  Eleanor M Pritchard; Michael A Dyer; R Kiplin Guy
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

Review 7.  Current management strategies for intraocular retinoblastoma.

Authors:  Jonathan W Kim; David H Abramson; Ira J Dunkel
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Treatment of retinoblastoma: current status and future perspectives.

Authors:  Carlos Rodriguez-Galindo; Guillermo L Chantada; Barrett G Haik; Matthew W Wilson
Journal:  Curr Treat Options Neurol       Date:  2007-07       Impact factor: 3.598

9.  Rabbit model of retinoblastoma.

Authors:  Shin Jeong Kang; Hans E Grossniklaus
Journal:  J Biomed Biotechnol       Date:  2010-12-28

10.  Current therapy and recent advances in the management of retinoblastoma.

Authors:  Rachna Meel; Venkatraman Radhakrishnan; Sameer Bakhshi
Journal:  Indian J Med Paediatr Oncol       Date:  2012-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.